Log In
Print this Print this

PC Detect

  Manage Alerts
Collapse Summary General Information
Company Panacea Pharmaceuticals Inc.
DescriptionDiagnostic screening test for prostate cancer which measures blood levels of human aspartyl (asparaginyl) beta-hydroxylase (HAAH)
Molecular Target Not applicable
Mechanism of ActionDiagnostic
Therapeutic ModalityDiagnostics
Latest Stage of DevelopmentMarketed
Standard IndicationCancer, Diagnostic
Indication DetailsDiagnose prostate cancer as an adjunct to prostate-specific antigen (PSA) and digital rectal exam (DRE)
Regulatory Designation
PartnerPanacea Global Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today